Infectious-disease prevention and treatment

Agenda updated October 9; checked October 16. EMA schedules its bacteriophage-therapy workshop for October 30, 2026, 09:00–18:00 Amsterdam time (CET), with online participation. The agenda covers the clinical evidence and potential European regulatory framework for phage treatment of resistant infections.

This is a policy/evidence discussion, not a drug approval, new randomized result or harmonized authorization to use every phage product. No change to U.S. availability is established. The event page has a conflicting CEST broadcast heading; its dated agenda explicitly says CET.

Sources: EMA · source page; EMA · PDF document.

Remaining gaps: All saved named registry records and every page of bounded September 5–October 16 CT.gov discovery were retrieved; 355 discovery records were screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, complete harms and original audio/transcripts remain incomplete. Prior full successful-check dates are preserved. New completion labels for VAX-31 and VYD2311 do not add results beyond earlier disclosures; future-antibiotic/phage worldwide coverage remains selective.

Informal-source coverage: Targeted Reddit, interview, podcast and saved unresolved-claim searches were appraised selectively; original recordings and worldwide informal coverage remain incomplete. Routine anecdotes and reposts were not treated as new trial evidence. Original adibelivir Reddit post describes an October 9 non-substantial CTIS modification whose contents were unavailable. That routine, unverified administrative inference was not promoted to an efficacy or approval rumor.

Full coverage record.

First posted October 13, 2026. GSK’s NCT07872046 plans a randomized masked phase 3 study of 16,390 adults aged at least 50, with established coronary/peripheral/cerebrovascular disease or at least two cardiovascular risk factors, on standard care. Two recombinant-zoster-vaccine doses at day 1/month 2 are compared with placebo. Primary time to first three-point MACE comprises nonfatal myocardial infarction, nonfatal stroke or cardiovascular death, with follow-up up to month 74. The population therefore spans secondary prevention and high-risk primary prevention, not everyone with prior MI.

Status/limits/safety/U.S.: Not yet recruiting; no hazard ratio or adverse-event results. A vaccine’s established shingles indication does not establish approval or efficacy for CV prevention. This randomized outcomes trial is distinct from observational vaccine associations.

Timing: November 30, 2026 estimated start; November 25, 2032 estimated primary/final completion. These are registry estimates, not confirmed readout dates.

Sources: ClinicalTrials.gov · NCT07872046.

Published October 12, 2026; full report of an older completed trial. NCT05933525 randomized 63 healthy adults (safety set); 60 underwent ETEC H10407 challenge, 30 per arm. Once-daily oral bovine-antibody Travelan 1,200 mg for seven days produced moderate/severe diarrhea in 6/30 (20%) versus 10/30 (33.3%): reported protective efficacy 40%, 95% CI −82.2% to 82.1%, nonsignificant. The lower-than-planned placebo attack rate reduced power but does not establish efficacy. Secondary endpoints had no multiplicity adjustment.

Safety/limits: No deaths or serious adverse events; one possible pre-challenge drug reaction. Post-challenge 55 versus 109 events are event counts largely attributed to infection, not proportions harmed by treatment. Nine withdrew before six-month follow-up. Single-strain challenge is distinct from natural-exposure diarrhea; microbiome/inflammation markers are not clinical protection.

U.S./next: Marketed as a dietary supplement, not FDA-approved travelers’-diarrhea prevention. Larger confirmatory human studies and an investigational enteric formulation are undated. Earlier sponsor topline dates remain historical.

Sources: Nature · article; ClinicalTrials.gov · NCT05933525.

Historical baseline, recovered October 13, 2026. NCT06889701 began April 3, 2025 (actual) and now lists recruiting, 33 planned participants: three sentinel patients, twenty randomized open-label participants and ten in an expansion cohort. TNP-2092 50 mg intra-articularly is studied alongside background antibiotics; randomized controls receive local vancomycin plus systemic/background antibiotics. Primary adverse-event safety runs through day 187; cure and prosthesis preservation require separate comparative evidence.

Limits/safety/U.S.: No results posted. This is a formal investigational antibiotic program, not established treatment or proven resistance reversal. Existing co-treatment limits attribution. Next: January 2027 primary/final completion estimates, no promised publication date.

Sources: ClinicalTrials.gov · NCT06889701.

Remaining gaps: All saved named registry records retrieved and all pages of bounded September5/6–October13 CT.gov discovery downloaded; 325 records screened selectively. Retrieval is not full appraisal. Worldwide registries, all publications/regulatory files, comprehensive harms and full audio/transcripts remain incomplete; prior full successful-check dates preserved.

Informal-source coverage: Targeted antibiotics/phage/vaccine Reddit and interview searches returned older studies and routine treatment anecdotes. No specific attributable new development rumor selected; full podcast/talk transcripts not appraised.

Full coverage record.

First posted October 7, 2026. NCT07863401 plans 400 lung-transplant or allogeneic hematopoietic-stem-cell-transplant recipients in a randomized, open-label comparison of two RSV vaccination strategies. The record compares a single adjuvanted regimen with a two-dose nonadjuvanted recombinant prefusion-F regimen, with antibody-response assessment one month after completing vaccination in each transplant subcohort. The narrative and coded product names disagree, so exact product identity requires protocol clarification.

Limits/safety/U.S.: The narrative also refers to RSVpreF while intervention coding uses RSVpreF3; product identity needs protocol clarification, so no brand is assigned here. An antibody-rise endpoint is not measured protection from RSV hospitalization or death. No human outcomes or quantified harms are posted. This study does not create a new U.S. transplant-specific indication.

Next: Not yet recruiting; October 2026 start, June 2028 primary and May 2029 final completion are registry estimates at month precision. Public-result timing is unknown.

Primary registry.

Remaining gaps: All saved named NCT records refreshed and all pages of official overlap discovery screened (312 returned records). Search starts September 5/6 from the last full successful check, not October 6 alone. Incidental matches excluded; literature, international registries, all regulatory files and complete podcast/audio appraisal remain incomplete.; VAX-31 topline and earlier PLG0206/China RSV/TNP2092 events already saved and deduplicated. No actual STEPS-CF first dosing verified. Broader new-antibiotic human efficacy, regulator files, conference abstracts and long-acting infection-prevention census remain incomplete. Gepotidacin resistance paper has September 1 online date despite October issue; not relabeled new October news.

Informal-source coverage: Located Communicable E64 (October4, Emily McDonald/Marc Bonten with Sylvain Lother/Valentijn Schweitzer) and Children’s Colorado Charting Pediatrics October6 show notes. These discuss existing antibiotic evidence/ stewardship rather than a new-development claim; full audio unreviewed. Read original personalized-phage-guideline Reddit discussion; expert consensus is not randomized efficacy. No separate noteworthy new rumor selected.

Full coverage record.

Source date: October 5, 2026. Evidence: Sponsor topline and SEC-filed slides; OPUS-1 NCT07284654 randomized 4,047 adults, including 3,572 aged ≥50 and 475 aged 18–49.

At one month, all 28 shared-serotype primary noninferiority assessments and four unique/cross-reactive superiority assessments passed. Primary analysis allowed PCV20 and/or PCV21 comparators with multiplicity control. Individual PCV21 comparisons passed 17/19 at the >0.667 confidence-bound margin; serotypes 3 and 12F only met the historical >0.5 margin. Younger-to-older immune bridging passed all 32 assessments.

Safety: In adults ≥50, serious adverse events were 14/1,194 VAX-31, 13/1,195 PCV20 and 13/1,183 PCV21. Four deaths occurred (two VAX-31, two PCV21), all assessed unrelated; no vaccine-related serious events or AE discontinuations were reported.

Limits/U.S.: Six-month safety and antibody function do not directly measure pneumonia/mortality prevention or prove superiority in every comparison. Investigational, not approved.

Next: OPUS-2/3 and infant phase 2 data H1 2027; adult BLA H1 2028, sponsor forecasts.

Original sponsor release; SEC-filed trial slides; OPUS-1 registry.

Source date: October 5, 2026 first posting. Evidence: NCT07858916, phase 2b design (registry phase 2), not yet recruiting in China.

Forty planned adults with prosthetic-joint infection receive intra-articular TNP-2092 with background infection care. Two acute-infection groups randomize daily 14-day versus weekly four-week dosing, ten per arm; up to 20 chronic-infection patients form a separate cohort. Primary outcome is six-month treatment failure, including infection-related death or additional treatment.

Limits/safety/U.S.: Open-label, no placebo/usual-care-only comparator, and no posted results. This cannot establish superiority, safety or eradication of biofilm. U.S. approval/access for this investigational regimen is not established.

Next: October 2026 start, September 2027 primary and March 2028 final completion are estimated.

Primary registry.

Source date: October 6, 2026 first posting; registry-reported actual start August 21. Evidence: NCT07860216, recruiting phase 3 randomized masked trial in China.

The study plans 25,000 adults aged ≥60, comparing a recombinant RSV vaccine produced in CHO cells with saline placebo. Primary outcome is first RT-PCR-confirmed RSV lower-respiratory disease over the first surveillance season.

Limits/safety/U.S.: No clinical results, adverse-event rates or demonstrated efficacy. A protocol’s assumed vaccine efficacy is a sample-size assumption, not a trial result. Approval of other RSV products does not authorize this formulation; U.S. approval is not established here.

Next: Primary/final completion December 31, 2028 is estimated; public readout timing unknown.

Primary registry.

Source/event date: 2026-09-29. Evidence: Sponsor-only randomized phase 3 topline.

LIBERTY (NCT07655180) randomized 210 healthy adults aged 18–49 among VYD2311 250 mg, Comirnaty, or both. Six-day adverse events/injection reactions/hypersensitivity occurred in 56.5% with VYD2311 versus 91.4% with Comirnaty; systemic events occurred in 44.1% versus 68.1%. No VYD2311-related event exceeded grade 2; no arm reported hypersensitivity/anaphylaxis. This small, short comparison does not establish rare/long-term safety or prevention of COVID. The sponsor's 70–90% efficacy figure is a target, not an observed result. DECLARATION (NCT07298434) safety and neutralizing-titer data are forecast for October; clinical efficacy remains blinded, with unblinding dependent on events and a proposed conditional-approval path. Neither FDA approval nor a submitted application is established. VYD2311 remains investigational and is distinct from Pemgarda. Sponsor.

Next milestone: October 2026 — sponsor forecast for DECLARATION safety and neutralizing-titer topline; clinical efficacy remains blinded.

Sponsor; ClinicalTrials.gov · NCT07655180; ClinicalTrials.gov · NCT07298434.

Source/event date: 2026-09-24. Evidence: Institutional announcement of planned human research.

Fraunhofer and Leicester describe REPhRAME, a five-year European collaboration intended to test bacteriophages for recurrent urinary infections. A Frankfurt-led randomized clinical study is planned to compare phages alone, phages with antibiotics, and phages with gut-microbiota restoration. This is a credible human-stage research plan, not evidence of effectiveness. No trial ID, enrollment target, first dosing or result date was verified. It does not establish U.S. approval or availability. Fraunhofer, Leicester.

Next milestone: Trial protocol/registration and first participant dosing; dates unknown.

Fraunhofer; Leicester; sciencemediahub.eu · article.

Source date: 2026-09-17. Evidence: Sponsor-reported trial authorization; recovered overlap finding.

SASPiPhi reported MHRA authorization for a first-in-human phase 1b/2a engineered-phage study in cystic fibrosis with Pseudomonas lung infection. STEPS-CF/SASPject PT3.9 plans 44–64 participants at Liverpool and up to ten additional UK sites. Sponsor cites ISRCTN57413769.

Limitations: Authorization explicitly remains conditional on funding, insurance and final HRA authorization. Registry redirected to a holding page; design, recruitment and start date were not independently verified. The September 17 announcement is newly appraised, not a September 29 trial launch.

Safety: No clinical efficacy or safety outcomes yet.

U.S. status: No U.S. approval; UK trial authorization is not treatment availability.

Next milestone: Funding/insurance/HRA completion and actual first dosing; no dependable date announced.

SASPiPhi September 17 release; STEPS-CF registry; access unavailable.

Source date: 2026-09-09. Evidence: Recovered baseline: sponsor development update and registries. Baseline addition; not new news.

BV100, an intravenous rifabutin formulation, is in phase 3 combination testing for carbapenem-resistant Acinetobacter pneumonia. RIV-TARGET NCT07326540 is recruiting; actual start March 27, 2026. Randomized Part A compares BV100/low-dose polymyxin B with colistin/high-dose ampicillin-sulbactam; primary endpoint 28-day mortality. RIV-CARE NCT07431307 is a separate open-label randomized phase 2b combination study with a safety-primary endpoint.

Limitations: September sponsor target around 300 differs from older RIV-TARGET registry estimate 248. RIV-CARE’s February record remains not-yet-recruiting despite elapsed July estimate; sponsor September site-start/H2 first-patient forecasts do not verify initiation. No new efficacy result; prior small-study mortality claims not reappraised.

Safety: Combination antibacterial safety, including renal and neurologic toxicity, requires full trial data; no new comparative safety table reported.

U.S. status: Investigational; September 2 Fast Track designation is not approval.

Next milestone: Sponsor: RIV-TARGET DSMB by end-2026, topline early 2028; RIV-CARE first patient H2 2026 and interim H1 2027. Registry primary completion: December 30, 2027 and March 2028 respectively.

BioVersys September 9 update; RIV-TARGET registry; RIV-CARE registry; BioVersys Fast Track announcement.

Source date: 2026-09-16. Event date: 2026-09-16. Evidence: Peer-reviewed randomized noninferiority trial.

For selected surgically managed orthopedic infections with local antibiotic carriers, a short systemic course was noninferior to a longer course. 500 adults were randomized; 475 entered primary analysis. At 12 months, failure occurred in 26/234 (11.1%) assigned ≤7 days versus 34/241 (14.1%) assigned ≥4 weeks. Difference −3.0 percentage points (95% CI −9.0 to 3.0), against a 10-point noninferiority margin. Trial: NCT03806166.

Limitations: Open-label treatment with blinded endpoint adjudication. Do not extrapolate to infections without implanted local antibiotics or to all orthopedic/hardware infections. September 16 publication recovered in this overlap search, not a September 27 result.

Safety: Potential treatment-related symptoms at six weeks were 17.2% versus 45.2% (difference −28.0 points, 95% CI −36.4 to −19.6). Full serious-event tables not appraised.

U.S. status: Treatment-duration evidence, not a new antibiotic approval.

Next milestone: Clinical adoption and subgroup appraisal; no dated new readout announced.

Short or Long Antibiotic Regimens in Orthopaedics, PubMed; SOLARIO original NEJM article.

Source date: 2026-09-21. Event date: 2026-09-21. Evidence: Sponsor-reported FDA filing action.

FDA accepted Insmed’s supplemental application for full approval and broader MAC lung-disease use, with a January 28, 2027 action target. The application relies on phase 3b ENCORE: 425 participants with a new occurrence of MAC infection received ARIKAYCE plus azithromycin/ethambutol or placebo plus the same antibiotics. Respiratory symptoms and culture conversion are separate outcomes. Existing results are not newly generated by filing acceptance.

Limitations: Priority review is not approval; the release does not supply full numerical endpoint or safety tables.

Safety: The established product carries respiratory-risk warnings, including hypersensitivity pneumonitis, hemoptysis, bronchospasm and exacerbation of underlying lung disease; the sponsor reports no new ENCORE signal.

U.S. status: Current accelerated approval remains limited to adults with refractory MAC, limited alternatives and persistent positive cultures after at least six months of multidrug treatment. Earlier-line use remains under review.

Next milestone: January 28, 2027: sponsor-reported FDA action target, not guaranteed approval.

Insmed September 21 release.

Source date: 2026-09-11. Evidence: Investigator enrollment report and trial registry.

WVU reported its first participant in RETAIN, a controlled trial of PLG0206 irrigation alongside surgery and antibiotics for infected knee replacements. NCT07214311 is a recruiting randomized placebo-controlled phase 2/3 study targeting 240 participants. It measures treatment failure through 12 months after debridement, antibiotics and implant retention, with surgery, survival and function also tracked. The registry lists a February 3, 2026 global start; September is a site-enrollment report, not global trial initiation.

Limitations: This newly added formal antimicrobial program addresses biofilm-associated infection, not cartilage regeneration. Laboratory activity and earlier small studies do not establish superiority, broad resistant-infection efficacy or implant retention benefit.

Safety: No new comparative efficacy or safety results were reported.

U.S. status: Investigational; Orphan/Fast Track/QIDP designations are not approval.

Next milestone: September 2028 primary completion is the September 18 registry estimate; public results timing is unknown.

WVU investigator update, September 11; RETAIN registry.